Get the Stockscreener App
2.45
2.00%
-0.05
After Hours:
2.41
-0.04
-1.63%
Tuhura Biosciences Inc stock is traded at $2.45, with a volume of 518.53K.
It is down -2.00% in the last 24 hours and up +4.26% over the past month.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
See More
Previous Close:
$2.50
Open:
$2.5
24h Volume:
518.53K
Relative Volume:
0.53
Market Cap:
$156.02M
Revenue:
-
Net Income/Loss:
$-30.05M
P/E Ratio:
-3.8833
EPS:
-0.6309
Net Cash Flow:
$-27.71M
1W Performance:
-0.41%
1M Performance:
+4.26%
6M Performance:
+17.22%
1Y Performance:
-13.43%
1-Day Range:
$2.3104
$2.502
1-Week Range:
$2.27
$2.585
52-Week Range:
$0.41
$3.90
Tuhura Biosciences Inc Stock (HURA) Company Profile
Name
Tuhura Biosciences Inc
Sector
Industry
Phone
813-875-6600
Address
10500 UNIVERSITY CENTER DR., TAMPA
Compare HURA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
2.45 | 159.21M | 0 | -30.05M | -27.71M | -0.6309 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | Citizens | Mkt Outperform |
| Mar-03-25 | Initiated | H.C. Wainwright | Buy |
| Dec-19-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-05-24 | Initiated | Maxim Group | Buy |
Tuhura Biosciences Inc Stock (HURA) Latest News
HURA: Refining TBS-2025 Development Plan - Yahoo Finance
HURA Should I Buy - Intellectia AI
HURA News | TUHURA BIOSCIENCES INC (NASDAQ:HURA) - ChartMill
HURA Stock Price, Quote & Chart | TUHURA BIOSCIENCES INC (NASDAQ:HURA) - ChartMill
Leverage, Covenants and Royalty Drain: Why Tuhura Biosciences’ Parkview Credit Deal Heightens Liquidity and Dilution Risks - The Globe and Mail
TuHURA Biosciences Secures $50M Credit Facility and Reports Q1 2026 Financial Results, Advancing Phase 3 Immuno-Oncology Programs - Minichart
TuHURA Biosciences Extends Cash Runway and Advances Pipeline - TipRanks
TuHURA Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
TuHURA Biosciences, Inc. 1Q 2026: Revenue $0 Net loss $(7.54M), EPS $(0.13) — 10-Q Summary - TradingView
TuHURA Biosciences (HURA) adds $50M credit line amid $7.5M loss - Stock Titan
TuHURA Biosciences (Nasdaq: HURA) secures $50M credit facility and outlines Q1 2026 pipeline milestones - Stock Titan
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update - PR Newswire
Cancer-drug developer TuHURA gets FDA orphan status, $50M credit line - Stock Titan
TuHURA Biosciences, Inc. (HURA) Eps Diluted (TTM) - Zacks Investment Research
HURA Stock Chart | TUHURA BIOSCIENCES INC (NASDAQ:HURA) - ChartMill
TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference - ChartMill
TuHURA cancer immunotherapy firm plans H.C. Wainwright fireside chat May 19 - Stock Titan
TradingKey - TradingKey
TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Number of shareholders of TuHURA Biosciences, Inc. – NASDAQ:HURA - TradingView
HURA Stock Price and Chart — NASDAQ:HURA - TradingView
Tuhura Biosciences, Inc. 2025 Annual Report: Financial Results, Research & Development Expenses, and Key Business Highlights - Minichart
TuHURA Biosciences (NASDAQ: HURA) updates Kineta merger pro forma loss to $34.6M - Stock Titan
TuHURA Biosciences (NASDAQ: HURA) details 2025 loss and cash runway - Stock Titan
Citizens initiates TuHURA Biosciences stock with outperform rating By Investing.com - Investing.com South Africa
Citizens initiates TuHURA Biosciences stock with outperform rating - Investing.com
TuHURA Biosciences (NASDAQ:HURA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
TuHURA Biosciences names Amanda Garofalo as clinical operations SVP By Investing.com - Investing.com Nigeria
Tuhura Biosciences secures $50 million credit facility, extends cash runway to 2028 - MSN
TuHURA Biosciences secures $50M credit facility from affiliate By Investing.com - Investing.com India
HURA (TuHURA Biosciences Inc.) posts 28.2 percent negative Q4 2025 EPS surprise, with shares falling 1.35 percent today.Community Risk Signals - UBND thành phố Hải Phòng
TuHURA Biosciences secures $50M credit facility from affiliate - Investing.com
TuHURA Biosciences Secures $50 Million Credit Facility - TipRanks
TuHURA Biosciences (Nasdaq: HURA) adds $50M credit line and IFx-2.0 royalty - Stock Titan
TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028 - PR Newswire
TuHURA Biosciences Advances Cancer Drug Trials Following 2025 Results - HarianBasis.co
5 Unstoppable Stocks That Could Double Your Money - Insider Monkey
Is TuHURA Biosciences (HURA) One of the Unstoppable Stocks That Could Double Your Money? - Insider Monkey
TuHURA Biosciences (HURA) Stock Abandons TuHURA Biosciences (HURA) Stock (Risk Aversion) 2026-04-16Momentum Signals - UBND thành phố Hải Phòng
Rodman & Renshaw initiates TuHURA Biosciences stock with buy rating By Investing.com - Investing.com Australia
Rodman & Renshaw Initiates TuHURA Biosciences(HURA.US) With Buy Rating, Announces Target Price $7 - Moomoo
TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Rodman & Renshaw initiates TuHURA Biosciences stock with buy rating - Investing.com
TuHURA Biosciences (NASDAQ:HURA) Raised to Hold at Wall Street Zen - MarketBeat
Equities Analysts Set Expectations for HURA FY2026 Earnings - MarketBeat
Brookline Capital Markets Comments on HURA Q1 Earnings - MarketBeat
Downgrade Watch: What is the target price for TuHURA Biosciences Inc stockWeekly Market Summary & AI Forecasted Stock Moves - baoquankhu1.vn
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
FY2029 EPS Forecast for TuHURA Biosciences Lifted by Analyst - MarketBeat
HURA.O PE Ratio & Valuation, Is HURA.O Overvalued - Intellectia AI
Aug Rallies: Does TuHURA Biosciences Inc. align with a passive investing strategyTrade Volume Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
Tuhura Biosciences Inc Stock (HURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):